📊 AKBA Key Takeaways
Is Akebia Therapeutics, Inc. (AKBA) a Good Investment?
Akebia demonstrates strong revenue growth of 47.5% YoY, but fundamental financial health is deteriorating with negative operating cash flow of -$21.2M, unprofitable operations, and dangerously low stockholders' equity of only $27.4M against $335.1M in liabilities. The 1.79x debt-to-equity ratio combined with ongoing cash burn creates material financial distress risk despite the substantial $162.6M cash position.
Akebia Therapeutics shows improving operating fundamentals, with positive operating income and strong free cash flow generation relative to revenue. However, the company still posted a net loss, carries meaningful leverage against a thin equity base, and lacks visible year-over-year trend data here, which limits conviction on the durability of the recent improvement.
Akebia Therapeutics, Inc. Key Strengths (AKBA)
- Strong revenue growth of 47.5% YoY demonstrates market traction and product demand
- Substantial absolute cash balance of $162.6M provides approximately 8 quarters of runway at current burn rates
- Improving diluted EPS trend with 93.9% YoY improvement, showing progress toward profitability
- Positive operating income and a 9.9% operating margin indicate the core business is currently generating operating profit
- Strong operating cash flow and free cash flow provide near-term financial flexibility, supported by $184.84M in cash
- Liquidity appears adequate with a 1.55x current ratio and 1.46x quick ratio
AKBA Stock Risks: Akebia Therapeutics, Inc. Investment Risks
- Negative operating cash flow of -$21.2M and free cash flow of -$21.3M indicate the company is burning cash despite revenue growth
- Critically low stockholders' equity of $27.4M represents only 7.5% of total assets, creating severe financial stress risk and high likelihood of dilutive capital raises
- High leverage with debt-to-equity ratio of 1.79x combined with negative profitability increases default risk and limits financial flexibility
- Net income remains negative, showing that profitability is not yet fully established
- Leverage is elevated relative to equity, with debt/equity of 1.48x and only $32.61M of stockholders equity
- Growth quality is harder to assess because year-over-year revenue and earnings trend data are not available in this snapshot
Key Metrics to Watch
- Quarterly operating cash flow trend and path to cash flow breakeven
- Stockholders' equity stability and risk of material dilution from future capital raises
- Operating margin progression toward profitability (currently -8.8%)
- Sustained net income improvement and operating margin durability
- Cash burn or free cash flow consistency relative to liabilities and debt levels
Akebia Therapeutics, Inc. (AKBA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Akebia Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
AKBA Profit Margin, ROE & Profitability Analysis
AKBA vs Healthcare Sector: How Akebia Therapeutics, Inc. Compares
How Akebia Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Akebia Therapeutics, Inc. Stock Overvalued? AKBA Valuation Analysis 2026
Based on fundamental analysis, Akebia Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Akebia Therapeutics, Inc. Balance Sheet: AKBA Debt, Cash & Liquidity
AKBA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Akebia Therapeutics, Inc.'s revenue has declined by 29% over the 5-year period, indicating business contraction. The most recent EPS of $-0.28 indicates the company is currently unprofitable.
AKBA Revenue Growth, EPS Growth & YoY Performance
AKBA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $53.5M | $6.1M | $0.03 |
| Q3 2025 | $37.4M | $247.0K | $0.00 |
| Q2 2025 | $43.6M | $247.0K | $0.00 |
| Q1 2025 | $32.6M | $6.1M | $0.03 |
| Q3 2024 | $37.4M | -$8.6M | $-0.08 |
| Q2 2024 | $43.6M | -$8.6M | $-0.04 |
| Q1 2024 | $32.6M | -$18.0M | $-0.09 |
| Q3 2023 | $42.0M | -$11.2M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Akebia Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
AKBA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Akebia Therapeutics, Inc. (CIK: 0001517022)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AKBA
What is the AI rating for AKBA?
Akebia Therapeutics, Inc. (AKBA) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AKBA's key strengths?
Claude: Strong revenue growth of 47.5% YoY demonstrates market traction and product demand. Substantial absolute cash balance of $162.6M provides approximately 8 quarters of runway at current burn rates. ChatGPT: Positive operating income and a 9.9% operating margin indicate the core business is currently generating operating profit. Strong operating cash flow and free cash flow provide near-term financial flexibility, supported by $184.84M in cash.
What are the risks of investing in AKBA?
Claude: Negative operating cash flow of -$21.2M and free cash flow of -$21.3M indicate the company is burning cash despite revenue growth. Critically low stockholders' equity of $27.4M represents only 7.5% of total assets, creating severe financial stress risk and high likelihood of dilutive capital raises. ChatGPT: Net income remains negative, showing that profitability is not yet fully established. Leverage is elevated relative to equity, with debt/equity of 1.48x and only $32.61M of stockholders equity.
What is AKBA's revenue and growth?
Akebia Therapeutics, Inc. reported revenue of $53.5M.
Does AKBA pay dividends?
Akebia Therapeutics, Inc. does not currently pay dividends.
Where can I find AKBA SEC filings?
Official SEC filings for Akebia Therapeutics, Inc. (CIK: 0001517022) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AKBA's EPS?
Akebia Therapeutics, Inc. has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AKBA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Akebia Therapeutics, Inc. has a C grade with 66% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AKBA stock overvalued or undervalued?
Valuation metrics for AKBA: ROE of -33.1% (sector avg: 15%), net margin of -16.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AKBA's AI grade for 2026?
Our dual AI analysis gives Akebia Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AKBA's free cash flow?
Akebia Therapeutics, Inc.'s operating cash flow is $-21.2M, with capital expenditures of $62.0K. FCF margin is -39.7%.
How does AKBA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -16.9% (avg: 12%), ROE -33.1% (avg: 15%), current ratio 1.40 (avg: 2).
Is Akebia Therapeutics, Inc. carrying too much debt?
AKBA has a debt-to-equity ratio of 1.79x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.40 suggests adequate short-term liquidity.